Effects of pregnancy on the pharmacokinetics of metformin by Liao, M.Z. et al.
Effects of Pregnancy on the Pharmacokinetics of Metformin
Michael Z. Liao, Shannon K. Flood Nichols, Mahmoud Ahmed, Shannon Clark, Gary D. Hankins,
Steve Caritis, Raman Venkataramanan, David Haas, Sara K. Quinney, Laura S. Haneline,
Alan T. Tita, Tracy Manuck, Joanne Wang, Kenneth E. Thummel, Linda Morris Brown,
Zhaoxia Ren, Thomas R. Easterling, and Mary F. Hebert
University of Washington, Departments of Pharmaceutics (M.Z.L., J.W., K.E.T.), Obstetrics and Gynecology (T.R.E., M.F.H.), and
Pharmacy (T.R.E., M.F.H.), Seattle, Washington; Madigan Army Medical Center, Division of Maternal-Fetal Medicine, Department of
Obstetrics and Gynecology, Tacoma, Washington (S.K.F.N.); University of Texas Medical Branch in Galveston, Department of
Obstetrics and Gynecology, Galveston, Texas (M.A., S.Cl., G.D.H.); University of Pittsburgh, Departments of Obstetrics and
Gynecology (S.Ca.), Pharmacy and Pharmaceutical Sciences (R.V.), Pittsburgh, Pennsylvania; Indiana University, Departments of
Obstetrics and Gynecology (D.H., S.K.Q.) and Pediatrics (L.S.H.), Indianapolis, Indiana; University of Alabama at Birmingham,
Department of Obstetrics and Gynecology, Birmingham, Alabama (A.T.T.); University of North Carolina, Department of Obstetrics
and Gynecology, Chapel Hill, North Carolina (T.M.); Biostatistics and Epidemiology Division, Environmental and Health Science Unit,
RTI International, Rockville, Maryland (L.M.B.); and Obstetric and Pediatric Pharmacology and Therapeutic Branch, Eunice Kennedy
Shriver National Institute of Child Health and Human Development, Bethesda, Maryland (Z.R.)
Received June 24, 2019; accepted December 30, 2019
ABSTRACT
This study’s primary objective was to fully characterize the phar-
macokinetics of metformin in pregnant women with gestational
diabetes mellitus (GDM) versus nonpregnant controls. Steady-state
oral metformin pharmacokinetics in pregnant women with GDM
receiving either metformin monotherapy (n 5 24) or a combination
with glyburide (n5 30) as well as in nonpregnant women with type 2
diabetes mellitus (T2DM) (n 5 24) were determined utilizing non-
compartmental techniques. Maternal and umbilical cord blood
samples were collected at delivery from 38 women. With both 500-
and 1000-mg doses,metformin bioavailability, volume of distribution
beta (Vb), clearance, and renal clearance were significantly in-
creased during pregnancy. In addition, in the women receiving
metformin 500 mg, significantly higher metformin apparent oral
clearance (CL/F) (27%), weight-adjusted renal secretion clearance
(64%), and apparent oral volume of distribution beta (Vb/F) (33%)
were seen during pregnancy. Creatinine clearance was significantly
higher during pregnancy. Increasing metformin dose from 500 to
1000 mg orally twice daily significantly increased Vb/F by 28%,
weight-adjusted Vb/F by 32%andCL/F by 25%, andweight-adjusted
CL/F by 28% during pregnancy. Mean metformin umbilical cord
arterial-to-venous plasma concentration ratio was 1.06 0.1, venous
umbilical cord-to-maternal concentration ratio was 1.4 6 0.5, and
arterial umbilical cord-to-maternal concentration ratio was 1.5 6 0.5.
Systemic exposure after a 500-mg dose of metformin was lower during
pregnancy compared with the nonpregnant women with T2DM.
However, in patients receiving metformin 1000 mg, changes in esti-
mated bioavailability during pregnancy offset the changes in clearance
leading to no significant change in CL/F with the higher dose.
SIGNIFICANCE STATEMENT
Gestational diabetes mellitus complicates 5%–13% of pregnancies
and is often treated with metformin. Pregnant women undergo
physiological changes that alter drug disposition. Preliminary data
suggest that pregnancy lowers metformin concentrations, poten-
tially affecting efficacy and safety. This study definitively describes
pregnancy’s effects on metformin pharmacokinetics and expands
the mechanistic understanding of pharmacokinetic changes across
the dosage range. Here we report the nonlinearity of metformin
pharmacokinetics and the increase in bioavailability, clearance,
renal clearance, and volume of distribution during pregnancy.
Introduction
Gestational diabetes mellitus (GDM) complicates 5%–13% of
pregnancies in the United States. (Hunt and Schuller, 2007). GDM
is associated with carbohydrate intolerance resulting in hypergly-
cemia of variable severity (World Health Organization, 2014).
GDM is associated with increased risk for maternal infections,
traumatic deliveries, hypertensive disorders, and preeclampsia as
well as neonatal hypoglycemia, respiratory distress syndrome,
macrosomia, polyhydramnios, shoulder dystocia, and kernicterus
(Bryson et al., 2003; Reece, 2010). Surgical deliveries are much
more common in women with GDM. Although GDM resolves after
pregnancy, these women have an increased risk of type 2 diabetes
mellitus (T2DM) later in life (Kitzmiller et al., 2007; Dabelea and
Crume, 2011).
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Historically, insulin has been the mainstay of GDM pharmacological
treatment. However, because of ease of administration, lower cost, and
comparable efficacy, oral hypoglycemic agents are now commonly used
in the management of GDM. Metformin, an oral antihyperglycemic
biguanide frequently used in the treatment of GDM, decreases insulin
resistance (DeFronzo, 1999; Winder and Hardie, 1999; Zhou et al.,
2001). Dosage strategies for pregnant women with GDM typically
follow the Food and Drug Administration–approved dosage range for
metformin in nonpregnant subjects with T2DM. Metformin is a small,
basic compound with a high unbound fraction (Scheen, 1996). In
addition, it is a substrate for organic cation transporters (OCTs) (Wang
et al., 2002; Kimura et al., 2005; Tanihara et al., 2007) and, after a 500-
mg dose, almost entirely excreted unchanged in the urine (Pentikäinen
et al., 1979; Zhou et al., 2007; Graham et al., 2011). OCT2 (encoded by
SCL22A2) has been proposed to play a critical role in the pharmaco-
kinetics (PK) of metformin. Metformin is actively transported from the
circulation into renal epithelial cells primarily by OCT2 leading to net
renal secretion (Takane et al., 2008). As a strong base with pKa of 11.5,
metformin’s net tubular secretion is not likely to be subject to passive
tubular reabsorption (Scheen, 1996). Decreased activity of OCT2 in
nonpregnant subjects due to genetic differences or drug-drug interac-
tions with inhibitors, such as cimetidine, results in 30%–60% decrease in
metformin renal and net renal secretion clearances and up to 74% in-
crease in area under the concentration-time curve (AUC) (Song et al.,
2008; Wang et al., 2008; Chen et al., 2009; Blackhall et al., 2010;
Dumitras et al., 2013). Renal excretion of metformin from tubular cells
into the urine is mediated through the multidrug and toxin extrusion
proteins (MATEs) 1 and 2-K (MATE1/SLC47A1 and MATE2-K/
SLC47A2) (Sato et al., 2008; Tsuda et al., 2009a,b; Ito et al., 2012). In
addition to OCT2, MATE1, and MATE2-K, metformin is also a sub-
strate of OCT1 (SLC22A1) and the plasma membrane monoamine
transporter (PMAT). OCT1 is predominantly expressed in the liver but
also has been reported to be expressed on the apical side of both the
proximal and distal tubules in the kidney (Tzvetkov et al., 2009). PMAT
(SLC29A4) is expressed on the apical membrane of intestinal epithelial
cells and has been suggested to be involved in intestinal absorption of
metformin (Zhou et al., 2007). Finally, metformin crosses the placenta
via active transport. OCT3 is expressed on the basal (fetal-facing)
membrane of the syncytiotrophoblasts in the placenta and transports
metformin into the fetal circulation (Lee et al., 2018). Umbilical cord
concentrations of metformin at the time of delivery have been reported to
be 50% to exceeding maternal concentrations in some cases (Hague
et al., 2003; Vanky et al., 2005; Charles et al., 2006). Glyburide has not
been reported to interact with metformin, impair renal filtration, or alter
any of the drug transporters involved with metformin disposition.
Preliminary data suggest that the pharmacokinetics of metformin are
altered by pregnancy (Eyal et al., 2010). The primary objective of this study
was to fully characterize the pharmacokinetics of metformin in pregnant
women with GDM as compared with nonpregnant women with T2DM.
Materials and Methods
This was a multicenter, prospective, randomized phase I–II PK study
(clinicaltrials.gov identifier NCT01329016). We examined the time course of
orally administered steady-state metformin in the plasma of pregnant women with
GDM receiving either metformin monotherapy (n 5 24) or a combination with
glyburide (n 5 30) as well as metformin monotherapy in nonpregnant women
with T2DM (n 5 24). The primary endpoint and full study design will be
published elsewhere. The studywas approved by the institutional review boards at
the University of Washington, Madigan Army Medical Center, University of
TexasMedical Branch in Galveston, University of Pittsburgh, Indiana University,
University of Utah Health Care, University of Alabama at Birmingham, and RTI
International and conducted in accordance with their guidelines. All subjects gave
written informed consent.
Subjects
GDM. Women 18–45 years of age with singleton pregnancies were included
after receiving a diagnosis of GDM based on either a 1-hour glucose tolerance test
(50 g) . 185 mg/dl, 2-hour oral glucose tolerance test (75 g) with one or more
values meeting or exceeding the International Association of Diabetes and
Pregnancy Study Groups Consensus Panel Guidelines (Sugawara et al., 2005), or
3-hour oral glucose tolerance test (100 g) with two or more values meeting or
exceeding Carpenter and Coustan designations (Carpenter and Coustan, 1982)
and failure to achieve glycemic control with dietary therapy. Women were
excluded if they were taking medications expected to interact with metformin or
alter blood glucose concentrations or had any of the following: serum creatinine
.1.2 mg/dl, hematocrit,28%, allergy to metformin, significant hepatic disease,
congestive heart failure, history of myocardial infarction, moderate to severe
pulmonary disease, adrenal insufficiency, or pituitary insufficiency.
T2DM. Nonpregnant female subjects with T2DM 18–45 years of age who
were receiving metformin were included in the study. Thirteen nonpregnant
subjects were included based on the above criteria. In addition, we included 11
female, nonpregnant 24–44-year-old subjects with T2DM from another similar
study in which subjects received the same formulation of metformin and
underwent the same steady-state metformin pharmacokinetic sample collections
described below (Eyal et al., 2010). Subjects were excluded for serum creatinine
.1.2 mg/dl and hematocrit ,28%.
Dosing Regimen
Subjects with GDM were randomized after diagnosis but prior to 33 weeks
gestation to metformin monotherapy, glyburide monotherapy, or metformin and
glyburide combination therapy. Results from the glyburide monotherapy group are
not reported in this paper. Metformin dosage was initiated at 500 or 1000 mg orally
twice daily and titrated based on clinical need. Metformin immediate-release tablets
were provided by the investigators for treatment of subjects with GDM and for the
3 days prior to the PK study for nonpregnant subjects with T2DM. Subjects with
T2DM were not randomized to treatment. Rather, they received metformin for
therapeutic reasons, and dosages were titrated without regard to the study. Subjects
recorded on a calendar the time each metformin dose was taken for the 3 days prior
to the pharmacokinetic study day, and pill counts were performed to assess
adherence. Except for clear liquids, subjects fasted for$5 hours prior to study drug
administration on the PK study day. Metformin was administered simultaneously
with the initiation of a standardizedmeal containing two slices of whole-wheat toast,
two teaspoons margarine, and 240 ml Boost Plus consumed within 10 minutes.
Sample Collection
On the day of the metformin PK study, serial blood samples were collected as
follows: predose, then 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours postdose,
truncated to the dosing interval for measurement of metformin plasma concen-
trations. Urine was collected in 4-hour intervals as follows: predose and then 0–4,
4–8, and 8–12 hours postdosing, truncated to the dosing interval. When possible,
maternal as well as umbilical cord venous and arterial blood samples were collected
at the time of delivery for measurement of plasma metformin concentrations. Blood
samples were collected in heparinized tubes, and plasma was isolated by
centrifugation and stored at 280C until analysis. Urine was refrigerated until
completion of the collection interval then stored at 280C until analysis.
ABBREVIATIONS: Ae, amount of metformin excreted in the urine unchanged; AUC, area under the plasma concentration-time curve; Clast, last
measurable concentration; CL, clearance; CL/F, apparent oral clearance; CLR, renal clearance; CLsec, renal secretion clearance; CrCL, creatinine
clearance; F, bioavailability; GDM, gestational diabetes mellitus; k, elimination rate constant; MATE, multidrug and toxin extrusion protein; OCT,
organic cation transporter; PK, pharmacokinetics; PMAT, plasma membrane monoamine transporter; T2DM, type 2 diabetes mellitus; Tmax, time to
maximum concentration; Vb, volume of distribution beta; Vb/F, apparent oral Vb.
Plasma and Urine Metformin Analysis
Metformin plasma andurine concentrationsweremeasured utilizing a validated
liquid chromatography with tandem mass spectrometry assay as previously
described (Zhang et al., 2015). The lower limits of quantitation were 4.95 ng/ml
for plasma and 30mg/ml for urine. For plasma, the coefficients of variation for this
method were 2.6%–11.9% for intraday and 2.1%–6.4% for interday, and accuracy
was 96%–100%. For urine, the CV for this method was ,14% for intraday and
interday, and accuracy was 94%–105%.
Genotyping
DNA was isolated from whole blood, and genotypes were determined
using validated TaqMan assays. Maternal and umbilical cord samples were
assayed for OCT1: SLC22A1 (rs622342); OCT2: SLC22A2c.808G.T
polymorphism (rs316019); MATE1: SLC47A1 (rs2289668 and rs8065082);
MATE2-K: -130G.A polymorphism (rs12943590); and PMAT (rs2685753 and
rs6971788).
Steady-State Pharmacokinetics Analysis
Steady-state metformin PK parameters were estimated using standard non-
compartmental techniques. Maximum concentration and time to maximum
concentration (Tmax) were determined from the measured concentrations. AUC
was estimated using the linear trapezoidal rule. When concentrations fell below
the lower limit of quantification for the assay prior to the end of the dosing
interval, the concentration at the end of the dosing interval was estimated by
extrapolating the predicted concentration based on the regression line from the
time of the last measurable concentration (Clast) with the elimination rate constant
(k) using Cend of dosing interval 5 Clast • e2kt, in which t was the time between Clast
and the end of the dosing interval. The elimination rate constant, k, was
determined by log-linear regression of the terminal slope. Apparent oral clear-
ance (CL/F) was estimated by CL/F 5 dose/AUC. Apparent oral volume of
distribution beta (Vb/F) was estimated by Vb/F 5 (CL/F)/kelim. Half-life (T1/2)
was estimated by T1/2 5 ln(2)/k over a period of ;2 half-lives. Renal clearance
(CLR) was determinedwith amount of metformin excreted in the urine unchanged
(Ae) by Ae/AUC. Metformin net renal secretion clearance (CLsec) was estimated
with creatinine clearance (CrCL) byCLsec5CLR2 (fuCrCL), in which fuwas
the unbound fraction of metformin in plasma and was assumed to be 1 (Scheen,
1996). Creatinine clearance was estimated by CrCL5 [(Uv)(UCr)]/[(SCr)(time)],
where Uv5 urine volume, UCr5 urine creatinine, and SCr5 serum creatinine.
The percent of dose recovered in the urine was determined by Ae/dose  100.
Metformin is not metabolized, has negligible biliary excretion, and is eliminated
exclusively by the kidneys (Pentikäinen et al., 1979). A study reported that an
intravenous dose of radiolabeled metformin was completely recovered from urine
over 48 hours with no radioactivity found in feces (Pentikäinen et al., 1979).
Therefore, for metformin, it is acceptable to estimate bioavailability (F) by F5 Ae/
dose (Beckmann, 1969; Pentikäinen et al., 1979; Sambol et al., 1996a; Gong et al.,
2012; Zamek-Gliszczynski et al., 2013). Volume of distribution beta (Vb) and CL
were estimated by Vb 5 (Vb/F)  F and CL 5 (CL/F)  F. Pharmacokinetic
parameters were adjusted based on actual body weights.
Statistical Analysis
Mann-Whitney test was used to compare PK parameters for monotherapy
versus combination therapy for 500- and 1000-mg doses separately, compare all
500-mg doses with all 1000-mg doses, and compare PK parameters in pregnant
with nonpregnant subjects for 500- and 1000-mg doses separately. Results are
reported as mean 6 S.D. for the above analyses. In addition, all data were
combined (all subjects and all doses), and the effects of pregnancy were assessed
using the linear mixed effects model controlling for random effects of dose and
weight of individuals and then compared by ANOVA. These results are reported
as mean 6 S.E.M. P # 0.05 was considered significant.
Results
Fifty-seven subjects with GDM at 26–38 weeks gestation (27 White,
19 Hispanic/Latina, one Native American, eight Black, and two Asian)
and 24 nonpregnant subjects with T2DM (eight White, nine Hispanic/
Latina, one Native American, five Black, and one Asian) participated in
this study. Metformin daily doses ranged from 1000 to 2000 mg/day in
two divided doses, with the exception of four subjects who were taking
metformin three times per day. We were unable to determine half-life
and apparent oral volume of distribution in three subjects with GDM and
one subject with T2DM because of termination of sample collection
prior to reaching the terminal elimination phase.
Figure 1 depicts mean steady-state metformin concentration-time
profiles in pregnant women with GDM and in nonpregnant women with
T2DM receiving 500 mg orally twice daily. Estimated steady-state
metformin PK parameters for pregnant women with GDM and non-
pregnant women with T2DM are reported in Table 1. For both 500- and
1000-mg doses, respectively, pregnancy significantly increased metfor-
min bioavailability (P , 0.01, P , 0.01), Vb (P , 0.001, P , 0.005),
weight-normalizedVb (P, 0.005,P, 0.005), CL (P, 0.01,P, 0.05),
weight-normalized CL (P , 0.01, P , 0.05), percent of dose excreted
unchanged in urine (P, 0.01, P, 0.01), CLR (P, 0.01,P, 0.05), and
weight-normalized CLR (P , 0.01, P , 0.05) as well as creatinine
clearance (P, 0.001, P, 0.001). Pregnancy also significantly increased
metformin Tmax (P , 0.01), Vb/F (P , 0.05), CL/F (P , 0.05), and
weight-normalized CLsec (P , 0.05) for women receiving 500 mg.
However, Vb/F, CL/F, and CLsec were not significantly different in
pregnant subjects when compared with nonpregnant subjects for those
women receiving 1000-mg doses. Half-life of metformin for both 500
and 1000 mg was not significantly altered during pregnancy.
All data were combined (all subjects and all doses), and the effects of
pregnancy were assessed using the linear mixed effects model
controlling for random effects of dose and subjects’ weight and then
compared by ANOVA. Multiple PK parameters were found to be
significantly altered by pregnancy. The presence of the pregnancy factor
corresponded to a significant increase of 0.166 0.04 for bioavailability
(x2 5 12.1, P 5 0.0005), 193 6 69 ml/min (x2 5 7.35, P 5 0.006)
for clearance, 77 6 18 l (x2 5 15.36, P 5 9*1025) for volume
of distribution, and 193 6 69 ml/min for renal clearance (x2 5 7.35,
P 5 0.006) of metformin. Pregnancy also significantly increased
creatinine clearance by 71 6 14 ml/min (x2 5 22.2, P 5 2*1026).
There was a trend toward an increase in metformin renal secretion
clearance during pregnancy (121 6 63 ml/min, x2 5 3.55, P 5 0.06).
When using the linear mixed effects model controlling for random
effects, pregnancy did not significantly alter half-life, time to maximum
concentration, apparent oral volume of distribution, or apparent oral
clearance.
As expected, Fig. 2 shows that mean steady-state metformin oral
concentration-time profiles are lower in pregnant women with GDM
receiving 500mg twice daily versus 1000mg twice daily.Metformin PK
Fig. 1. Mean (error bar S.D.) steady-state metformin (500 mg orally twice daily) in
pregnant women with gestation diabetes mellitus (n 5 39) and nonpregnant women
with type 2 diabetes mellitus (n 5 9). Circles indicate concentrations in women with
gestational diabetes mellitus, and squares indicate concentrations in women with
type 2 diabetes mellitus.
parameters during pregnancy comparing 500–1000mg doses were dose-
dependent. Doubling the dose increased Vb/F by 22% (368 6 133 L
vs. 4506 136 l,P, 0.02), weight-adjustedVb/F by 25% (4.06 1.7 l/kg
vs. 5.0 6 1.6 l/kg, P , 0.006), CL/F by 29% (1085 6 328 ml/min vs.
1405 6 384 ml/min, P , 0.02), and weight-adjusted CL/F by
33% (11.7 6 3.8 ml/min per kilogram vs. 15.6 6 4.5 ml/min per
kilogram, P , 0.02). Half-life, bioavailability, maximum concentration,
CL,Vb, percent of dose excreted unchanged in urine, CLR, andCLsec were
not significantly changed. Coadministration of metformin with glyburide
did not alter the estimated metformin PK parameters (unpublished data).
In both pregnant women with GDM and nonpregnant women with
T2DM, metformin renal clearance had a moderate correlation with
creatinine clearance (Fig. 3A: r 5 0.67, P , 0.0001) and an excellent
correlation with renal secretion clearance (Fig. 3B: r5 0.96, P, 0.0001).
Metformin renal secretion clearance had a weaker correlation with
creatinine clearance (r5 0.41, P, 0.001) (unpublished data). Metformin
apparent oral clearance poorly correlated with CrCL (r5 0.18, P5 0.06)
(unpublished data).
Out of 38 umbilical cord plasma samples collected, 14 arterial and
11 venous metformin concentrations were below the lower limit of
quantification. Mean duration from last maternal dose to time of sample
collection was 19 6 7.8 hours (range: 5.5–37.3 hours). The mean
measurable metformin plasma concentrations in the umbilical cord
arterial and venous samples were 2906 233 (range: 13–910 ng/ml) and
331 6 257 ng/ml (range: 11–1070 ng/ml), respectively. The mean
maternal metformin plasma concentration was 2626 231 ng/ml (range:
6–1020 ng/ml). The mean metformin umbilical cord arterial-to-venous
plasma concentration ratio was 1.0 6 0.1. The mean metformin
umbilical cord arterial-to-maternal plasma concentration ratio was 1.5
6 0.5 and umbilical cord venous-to-maternal concentration ratio was 1.4
6 0.5. Figure 4 depicts the relationship between time post–last dose and
metformin umbilical cord-to-maternal plasma concentration ratios
(r 5 0.3, P 5 0.1).
Genotype for various relevant metformin drug transporters was
determined. OCT1: SLC22A1 (rs622342); OCT2: SLC22A2c.808G.T
polymorphism (rs316019); MATE1: SLC47A1 (rs2289668 and
rs8065082); MATE2-K: -130G.A polymorphism (rs12943590); and
PMAT (rs2685753 and rs6971788) were not significantly associated
with metformin AUC, CL/F, CL, CLsec, bioavailability, or umbilical
cord-to-maternal plasma concentration ratio.
Discussion
Pregnancy has been reported to alter the PK of many drugs, including
metformin (Anderson, 2005; Isoherranen and Thummel, 2013; Cos-
tantine, 2014). PK changes during pregnancy are challenging to predict.
Pregnancy alters gastric emptying, intestinal transit, organ blood flow,
blood volume, protein binding, body composition, drug-metabolizing
enzymes, and drug transporters expressions, which can influence the
overall drug exposure (Anderson, 2005; Isoherranen and Thummel,
2013). The current study rigorously evaluates metformin PK during
pregnancy in women with GDM and nonpregnant women with T2DM
and provides mechanistic insight into differences.
Metformin (500 mg) is eliminated almost exclusively by the kidneys
(Pentikäinen et al., 1979). It is not metabolized, and biliary excretion is
negligible in humans (Graham et al., 2011; Gong et al., 2012; Zamek-














F 0.64 6 0.2 0.49 6 0.08 ,0.01 0.53 6 0.11 0.37 6 0.14 ,0.01
Half-life (h) 4.2 6 1.1 4.0 6 0.8 0.4 4.3 6 0.7 3.7 6 0.6 0.2
Tmax (h) 2.6 6 1.3 2.1 6 0.5 ,0.01 2.4 6 1.1 2.2 6 1.3 0.7
VB/F (l) 368 6 133 276 6 52 ,0.05 450 6 136 486 6 207 0.6
VB/F (l/kg) 4.00 6 1.68 3.19 6 1.10 0.08 4.99 6 1.64 5.00 6 2.07 0.9
VB (l) 242 6 138 134 6 23 ,0.001 234 6 66 163 6 48 ,0.005
VB (l/kg) 2.6 6 1.6 1.5 6 0.3 ,0.005 2.6 6 0.9 1.7 6 0.6 ,0.005
CL/F (ml/min) 1085 6 328 854 6 230 ,0.05 1405 6 384 1678 6 574 0.4
CL/F (ml/min per kilogram) 11.7 6 3.8 9.5 6 2.4 0.05 15.6 6 4.5 17.5 6 6.5 0.3
CL (ml/min) 731 6 339 444 6 121 ,0.01 758 6 179 572 6 153 ,0.05
CL (ml/min per kilogram) 7.9 6 3.9 4.9 6 1.3 ,0.01 8.5 6 2.5 6.1 6 2.4 ,0.05
Percent of dose recovered in the urine
unchanged (%)
64 6 20 49 6 8 ,0.01 53 6 11 37 6 14 ,0.01
CLR (ml/min) 731 6 339 444 6 121 ,0.01 758 6 179 572 6 153 ,0.05
CLR (ml/min per kilogram) 7.9 6 3.9 4.9 6 1.3 ,0.01 8.5 6 2.5 6.1 6 2.4 ,0.05
CrCL (ml/min) 233 6 68 148 6 41 ,0.001 233 6 46 166 6 25 ,0.001
CLsec (ml/min) 497 6 312 296 6 97 0.06 530 6 168 406 6 143 0.1
CLsec (ml/min per kilogram) 5.4 6 3.6 3.3 6 1.1 ,0.05 5.9 6 2.3 4.3 6 2.0 0.2
Fig. 2. Mean (error bar S.D.) steady-state metformin concentration-time curves for
pregnant women receiving 500 mg orally twice daily (n 5 39) and 1000 mg orally
twice daily (n 5 15). Circles indicate concentration with the 500 mg cohort, and
squares indicate concentration with the 1000 mg cohort.
TABLE 1
Estimated metformin steady-state pharmacokinetic parameters for pregnant women with GDM and nonpregnant women with T2DM 
separated by dose
Results are reported as means 6 S.D. Mann-Whitney test was used to compare PK parameters for pregnant and nonpregnant women receiving either 500- or 1000-
mg doses. P , 0.05 was considered significant.
estimate of bioavailability (Beckmann, 1969; Pentikäinen et al., 1979;
Tucker et al., 1981; Sambol et al., 1996a). We found that metformin
bioavailability was significantly higher in pregnant women with GDM
compared with nonpregnant women with T2DM. The increase in
progesterone during pregnancy prolongs small intestine transit time,
which can increase absorption of metformin (Loebstein et al., 1997;
Marathe et al., 2000; Dawes andChowienczyk, 2001; Costantine, 2014).
Higher metformin bioavailability has also been reported with propanthe-
line, a drug that slows gastrointestinal motility (Marathe et al., 2000).
Higher bioavailability of metformin during pregnancy might also
occur because of upregulation of the uptake transporter processes in the
intestine. Currently, the molecular mechanism underlying metformin
intestinal absorption is not well-understood. Studies in the Caco-2
monolayer culture model suggest that metformin uptake involves
multiple transporters, including OCT1 and PMAT (Han et al., 2015).
The effect of pregnancy on the expression of these transporters is not
known. Limited information is available on xenobiotic absorption
during pregnancy; however, increased intestinal absorption of dietary
micronutrients is well-documented. In human and animal pregnancy,
there is a 2-fold increase in the intestinal absorption of calciummediated
by increases in 1,25-dihydroxyvitamin D and other mechanisms
(Kovacs and Kronenberg, 1997). Intestinal absorption of dietary iron
also increases during the second and third trimesters of pregnancy to
accommodate for the need to expand red blood cell mass (Food and
Nutrition Board, Institute ofMedicine, 2001). Absorption of dietary zinc
and vitamin B12 also increase during pregnancy (Hellegers et al., 1957;
Donangelo et al., 2005; Donangelo and King, 2012).
Our study demonstrates that metformin clearance and weight-adjusted
clearance were significantly higher during pregnancy. This is driven by
changes in metformin renal clearance. Renal clearance was significantly
higher during pregnancy and consistent with that previously reported by
Eyal et al. (2010). The pregnancy-related changes in renal clearance
appear to be largely influenced by increased active renal transport.
Figure 3B illustrates the strong correlation between metformin renal
clearance and net renal secretion clearance (r5 0.96, P, 0.0001). The
strong correlation was expected because net renal secretion clearance
makes up approximately two-thirds of metformin renal clearance.
Metformin active renal tubular transport has been reported to be
mediated by organic cation transporters and multidrug and toxin
extrusion proteins (Davison and Dunlop, 1980; Song et al., 2008; Wang
et al., 2008; Becker et al., 2009; Chen et al., 2009; Cheung and Lafayette,
2013). Metformin is a substrate for multiple OCTs, including OCT1,
OCT2, OCT3, PMAT, andMATEs. In humans, OCT2 andMATEs play
a major role in metformin renal clearance (Davison and Dunlop, 1980;
Song et al., 2008; Wang et al., 2008; Becker et al., 2009; Chen et al.,
2009; Ito et al., 2012; Cheung and Lafayette, 2013). Several studies
in vitro and in animals suggest that Oct2 expression and activity in the
kidney are regulated by steroidal hormones (Shu et al., 2001; Lee et al.,
2013; Han et al., 2015). In addition, it has been suggested that
epigenetics may play a role in OCT2 expression and variability in the
placenta (Saito et al., 2011). However, little is known about OCT2
regulation in human pregnancy. The mechanism for increased apparent
OCT2 activity during pregnancy warrants further study.
Metformin CLR is also influenced by renal filtration. Figure 3A
demonstrates the relationship between metformin CLR and CrCL (r 5
0.67, P, 0.0001). The correlation between metformin CLR and CrCL is
not as strong as that seen with net CLsec likely because of the major role
active transport plays in metformin CLR. Previous work reported as
much as a 40% increase in glomerular filtration rate and
10%–35% increase in renal blood flow during pregnancy (Cheung and
Lafayette, 2013). This is consistent with the higher CrCL (P, 0.00002)
and metformin CLR reported here.
In contrast to the PK changes reported in this study, Charles et al.
(2006) utilizing a population PK approach found no change in
metformin clearance during late pregnancy compared with nonpregnant
Fig. 3. (A) Correlation between creatinine clearance and metformin renal clearance
in pregnant women with GDM (solid circles) and nonpregnant women with T2DM
(solid triangles) taking metformin 500 and 1000 mg orally twice daily. (B).
Correlation between metformin renal clearance and renal secretion clearance in
pregnant women with GDM (solid circles) and nonpregnant women with T2DM
(solid triangles) taking metformin 500 and 1000 mg orally twice daily (n 5 68).
Fig. 4. Ratios of umbilical cord arterial and venous plasma concentrations to
maternal concentrations as a function of duration between the last maternal
metformin dose and the time of sample collection. Solid circles represent metformin
umbilical cord arterial: maternal plasma concentration ratios. Solid triangles
represent metformin umbilical cord venous: maternal plasma concentration ratios.
patients. They used sparse sampling, with a median of two plasma
samples per patient, and fixed the bioavailability at 0.5. Their
approach likely contributed to the discrepancy in results. Hughes
et al. (2006) also conducted a study to evaluate the pharmacokinetics
of metformin in pregnancy and postpartum; however, they only
studied seven subjects. Of those seven subjects taking metformin
every 12 hours, four were studied for 8 hours and three for only
4 hours. This approach did not allow estimation of any PK parameters
except a truncated AUC.
CL/F was significantly (27%) higher in pregnant women than the
nonpregnant women who received a 500-mg dose. A higher CL/F will
result in lower systemic metformin exposure during pregnancy than
expected for a nonpregnant woman, potentially necessitating an in-
creased dose for the desired pharmacological effect. However, this was
not the case for women who received a 1000-mg dose. The higher
metformin bioavailability during pregnancy offset the increase in
metformin CL, leading to no significant change in CL/F in patients
receiving 1000 mg of metformin. In a pilot study, Eyal et al. (2010)
found no significant change in CL/F during pregnancy, but this was
a smaller study, and dose-based PK parameters were not estimated. In
a study by de Oliveira Baraldi et al. (2012), the PK of metformin was
studied in eight pregnant women with polycystic ovary syndrome and
nine pregnant women with type 2 diabetes mellitus receiving metformin
850mg orally every 12 hours. Their CL/F values were similar to our data
during pregnancy with the 1000-mg dose. They did not report on the
effect of dosage or pregnancy on metformin PK.
It has been previously reported that low functional OCT1 was
associated with lower metformin CL/F (Shu et al., 2008). Decreased
activity of OCT2 has been reported to decrease metformin CLR and
CLsec 30%–60% and increase AUC up to 74% (Song et al., 2008; Wang
et al., 2008; Chen et al., 2009). Others have reported that MATE1 and
MATE2-K are important for renal excretion (Sato et al., 2008; Tsuda
et al., 2009a,b; Ito et al., 2012) and PMAT for reabsorption of metformin
(Xia et al., 2007). In contrast to previous pharmacogenetics studies in
nonpregnant subjects described above that demonstrated differences in
metformin PK based on genotype (n5 26–208), we found no significant
association between OCT1, OCT2, MATE1, MATE2-K, or PMAT
genotype and metformin AUC, CL/F, CL, CLsec, bioavailability, or
umbilical cord-to-maternal plasma concentration ratio in our 77 pregnant
women. Similarly, Duong et al. (2013) found no significant relationship
between OCTs, MATEs, and PMAT gene variant and CL/F or AUC
(n 5 57). The limited number of patients in this study and the potential
confounding factor of pregnancy may have masked any genetic effect.
Metformin Vb was significantly higher during pregnancy (P, 0.001).
The presence of the fetus and placenta as well as the increase in total body
water can increase the volume of distribution of hydrophilic drugs, such as
metformin, and is likely the reason for the higher metformin Vb during
pregnancy. Vb/F was significantly higher in pregnant women receiving
the 500-mg dose; however, the higher bioavailability during pregnancy
offset the higher Vb leading to no significant change in Vb/F for pregnant
women taking 1000mg. TheVb/F in our studywas similar to that reported
by Eyal et al. (2010) during late pregnancy (4326 168 l) and de Oliveira
Baraldi et al. (2012) (T2DM: 491 l; range 419–798 l) but lower than that
reported by de Oliveira Baraldi et al. (2011) (551 l; range 385–1173 l and
polycystic ovary syndrome: 551 l; range 406–1037 l) (de Oliveira Baraldi
et al., 2012). In addition, the weight-normalized Vb/F was comparable to
that previously reported during late pregnancy by Eyal et al. (2010) (4.06
1.5 l/kg). Lastly, the Vb/F in our nonpregnant patients with T2DM was
similar to that reported by Sambol et al. (1996b) in nonpregnant healthy
volunteers (367 6 42 l).
Our current study demonstrated that increasing the metformin dose
from 500 to 1000 mg during pregnancy increased the CL/F and Vb/F
(P , 0.02, P , 0.02, respectively). This observation appears to be
driven primarily by the trend toward higher bioavailability with the
500-mg dose and minor differences in clearance and volume. A
decrease in bioavailability with increasing dose was also observed
in the nonpregnant population reported elsewhere (Tucker et al.,
1981). Tucker et al. (1981) reported that the bioavailability of
a 1500-mg dose of metformin was 9%–24% lower than with a 500-
mg dose (n 5 4). Sambol et al. (1996a) found that an 850-mg dose
of metformin had a bioavailability that was 12% lower than with
a 500-mg dose. These data are consistent with metformin having
capacity limited absorption. Although not reaching significance,
our current study found a trend toward a lower metformin bio-
availability with 1000-mg doses than with 500-mg (P 5 0.1) doses
during pregnancy. Metformin is highly water-soluble, therefore,
solubility is unlikely to be a factor in bioavailability dose dispropor-
tionality. In addition, metformin is largely ionized in the gastrointes-
tinal tract, which limits its permeability. Higher doses of metformin
may saturate the uptake transporters in the enterocytes, which would
lead to decreased absorption and bioavailability with higher doses
(Proctor et al., 2008).
Metformin half-life in our study was consistent with that previously
reported in other steady-state pharmacokinetic studies (de Oliveira
Baraldi et al., 2011, 2012). However, since these women were taking
metformin for therapeutic reasons, sampling duration was limited to the
dosing interval. Steady-state dosing is well-suited to demonstrate the
impact of a prolonged terminal half-life on drug exposure (AUC) but
limits the duration for sampling after dosing. Although our study design
did allow for rigorous estimation of the half-life during the dosing
interval with concentrations falling over;2 half-lives in the elimination
portion of the curve, it did not allow for estimation of the very prolonged
half-life that has been reported by Sambol et al. (1996a) between 12 and
48 hours after discontinuation of the drug.
Metformin umbilical cord-to-maternal plasma concentration ratios
range from 0.7 to 2.8, consistent with previous reports (Vanky et al.,
2005; Eyal et al., 2010; de Oliveira Baraldi et al., 2011). Given
metformin’s water solubility, it does not easily diffuse across
membranes, suggesting active transport of metformin from the
maternal to the fetal side. Metformin is a substrate for the serotonin
transporter and OCT3 (Rubinchik-Stern and Eyal, 2012; Han et al.,
2015), which are expressed in human placenta (Lee et al., 2018). In
addition, metformin plasma umbilical cord arterial-to-venous con-
centration ratio centered around 1 (r5 0.1), which is consistent with
insignificant fetal extraction of metformin. Similar results were
reported by de Oliveira Baraldi et al. (2011).
In conclusion, pregnancy significantly increases the F, CL, and Vb
of metformin. With lower doses, pregnancy also increases the CL/F
of metformin, suggesting that higher initial doses might be needed in
pregnant women. However, with higher doses, the changes in F
during pregnancy offset the changes in CL and Vb leading to no
significant change in CL/F and systemic exposure. In addition, we
have demonstrated the nonlinearity of metformin pharmacokinetics
during pregnancy, with a higher CL/F with higher metformin doses.
This finding appears to be primarily driven by the trend toward lower
F with higher metformin doses.
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